AcumaPimod 是一种有口服活性的p38 MAP激酶抑制剂，IC50值小于1 μM。

Acumapimod is an orally active inhibitor of p38α MAPK (IC50<1 μM).

Acumapimod increases survival and reduces the number of macrophages in bronchoalveolar lavage fluid (BALF) in a mouse model of infection with influenza H1N1 A/PR/8/34 when administered at a dose of 6 mg/kg[1]

In vivo, female BALB/c mice were infected intranasally with 150 pfu of influenza H1N1 A/Puerto Rico/8/34 and treated with Acumapimod(BCT197) (a closely related p38 MAPK inhibitor with an IC50 value of<1?μM, currently in clinical testing), dexamethasone or oseltamivir (Tamiflu) starting 24?h post infection. Body weight, bronchoalveolar lavage cells, cytokines, total protein and lactate dehydrogenase as well as serum cytokines were measured; a subset of animals was evaluated histopathologically[1].

836683-15-9

C22H19N5O2

385.427

BCT-197

DMSO:50 mg/mL (129.73 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years